Bicalutamide Dosage and Efficacy in Prostate Cancer Treatment

Efficacy and Treatment Outcomes

Clinical trials comparing enzalutamide to bicalutamide in castration-resistant prostate cancer showed superior progression-free survival with enzalutamide (15.7 vs 5.8 months), as recommended by the National Comprehensive Cancer Network 1, 2
The National Comprehensive Cancer Network suggests that bicalutamide may still be considered due to different side effect profiles and cost considerations, despite enzalutamide demonstrating superior progression-free survival in castration-resistant prostate cancer 1, 2

Bicalutamide monotherapy better preserves sexual interest and physical capacity compared to castration, which should be balanced against potential efficacy differences when selecting treatment, according to the National Comprehensive Cancer Network 2

The National Comprehensive Cancer Network and other major guidelines do not recommend the 30mg dose for prostate cancer treatment, citing reduced efficacy with lower doses 1, 2, 3